Obalon Therapeutics Prices Public Offering of Common Stock

Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced the pricing of an underwritten public offering of 5,454,545 shares of its common stock at a public offering price of $5.50 per share.
As quoted in the press release:

UBS Investment Bank, Canaccord Genuity and Stifel are acting as joint book-running managers for the offering. BTIG is acting as a co-manager.

The offering is being made pursuant to a shelf registration statement that was declared effective by the Securities and Exchange Commission (SEC) on November 17, 2017.

Click here to read the full press release.